This site is intended for US Healthcare Professionals only.
MENU

Publications

Browse the library of publications below for key research from ADC Therapeutics scientists.

Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial Alderuccio JP, et al. Lancet Haematology. Jan 2025
View Publication
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma Epperla N, et al. Blood Cancer Journal. Nov 2024
View Publication
Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine. Hamadani M, et al. eJHaem. Sep 2024
View Publication
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study Caimi PF, et al. Haematologica. Aug 2023
View Publication
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial Hamadani M, et al. Blood Adv. Jan 2024
View Publication
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine Caimi PF, et al. eJHaem. Nov 2023
View Publication
Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Chihara D, et al. Blood. Sep 2023
View Publication
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Caimi PF, et al. Lancet Oncol. May 2021
View Publication

Contact ADC Therapeutics

Submit a Medical Inquiry Reach out to the ADC Therapeutics team with your specific medical inquiry.
Contact Medical Affairs 1-855-690-0340
8:00 AM to 6:00 PM ET

Report Adverse Reactions or Product Complaints

To report suspected adverse events or product complaints, please call us at 1-855-690-0340 and select prompt 1. You may also call the FDA at 1-800-FDA-1088 or report suspected adverse events at www.fda.gov/medwatch.